Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms (Neptune)

A Randomized, Double-blind, Parallel Group, Placebo Controlled, Multi-center Study of Fixed Dose Combinations of Solifenacin Succinate (6 mg and 9 mg) With Tamsulosin Hydrochloride OCAS 0.4 mg and Tamsulosin Hydrochloride OCAS 0.4 mg Monotherapy, in Male Subjects With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) With a Substantial Storage Component

Clinical study to examine the efficacy, safety and tolerability of combination therapy of tamsulosin hydrochloride and solifenacin succinate compared to monotherapy of tamsulosin hydrochloride in the treatment of males with LUTS associated with BPH with a substantial storage component.

Study Overview

• Status: Completed
• Conditions: Lower Urinary Tract Symptoms; Benign Prostatic Hyperplasia
• Intervention / Treatment: Drug: Placebo tamsulosin hydrochloride OCAS 0.4 mg; Drug: Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg; Drug: Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg; Drug: tamsulosin hydrochloride OCAS 0.4 mg; Drug: tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg); Drug: tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)

• Study Type: Interventional
• Enrollment (Actual): 1334
• Phase: Phase 3

Contacts and Locations

Study Locations

• Austria
  • Innsbruck, Austria, 6020
  • Salzburg, Austria, 5020
  • Vienna, Austria, 1090
• Belarus
  • Minsk, Belarus, 220036
  • Minsk, Belarus, 220119
  • Minsk, Belarus, 220114
• Belgium
  • Antwerp, Belgium, 2020
  • Antwerp, Belgium, 2030
  • Assebroek, Belgium, 8310
  • Brussels, Belgium, 1090
  • Brussels, Belgium, 1200
  • Brussels, Belgium, 1070
  • Edegem, Belgium, 2650
  • Gent, Belgium, 9000
  • Kortrijk, Belgium, 8500
  • Leuven, Belgium, 3000
  • Liege 1, Belgium, 4000
  • Sint-Truiden, Belgium, 3800
  • Turnhout, Belgium, 2300
• Czechia
  • Hradec Kralove, Czechia, 500 02
  • Ostrava, Czechia, 700 30
  • Plzen, Czechia, 301 24
  • Prague, Czechia, 180 81
  • Roudnice nad Labem, Czechia, 413 01
  • Uherske Hradiste, Czechia, 686 08
  • Usti nad Labem, Czechia, 40001
  • Zdar nad Sazavou, Czechia, 591 01
• France
  • Aix en Provence, France, 13616
  • Angers, France, 49033
  • Bordeaux Cedex, France, 33076
  • Colmar Cedex, France, 68024
  • Dijon, France, 21000
  • Dijon, France, 21079
  • Lyon Cedex 3, France, 69437
  • Montlucon, France, 03100
  • Orleans Cedex 2, France, 45067
  • Paris, France, 75010
  • Paris Cedex 10, France, 75020
  • Paris Cedex 14, France, 75679
  • Pierre Benite, France, 69495
  • Rennes, France, 35033
  • Tours Cedex, France, 37044
• Germany
  • Bad Ems, Germany, 56130
  • Bautzen, Germany, 02625
  • Frankfurt, Germany, 65933
  • Hagenow, Germany, 19230
  • Halle Saale, Germany, 06132
  • Hamburg, Germany, 20253
  • Henningsdorf, Germany, 16761
  • Hettstedt, Germany, 06333
  • Koblenz, Germany, 56068
  • Leipzig, Germany, 04105
  • Leipzig, Germany, 04109
  • Lutherstadt Eisleben, Germany, 06295
  • Neustadt in Sachsen, Germany, 01844
  • Uetersen, Germany, 25436
• Hungary
  • Budapest, Hungary, 1204
  • Kormend, Hungary, 9900
  • Nyiregyhaza, Hungary, 4400
  • Sopron, Hungary, 9400
  • Szekszard, Hungary, 7100
  • Szentes, Hungary, 6601
  • Tatabanya, Hungary, 2800
• Italy
  • Avellino, Italy, 83100
  • Bari, Italy, 70124
  • Bergamo, Italy, 24125
  • Catania, Italy, 95124
  • Catanzaro, Italy, 88100
  • Florence, Italy, 50139
  • Palermo, Italy, 90146
  • Treviglio, Italy, 24047
  • Turin, Italy, 10154
• Netherlands
  • Amsterdam, Netherlands, 1100 AD
  • Apeldoorn, Netherlands, 7334 DZ
  • Doetinchem, Netherlands, 7009 BL
  • Eindhoven, Netherlands, 5623 EJ
  • Etten-Leur, Netherlands, 4872 LA
  • Maastricht, Netherlands, 6229 HX
  • Sneek, Netherlands, 8600 BA
  • Sneek, Netherlands, 8601 ZK
  • Tilburg, Netherlands, 5022 GC
  • Winterswijk, Netherlands, 7101 BN
• Poland
  • Bielsko Biala, Poland, 43-300
  • Bydgoszcz, Poland, 85-094
  • Krakow, Poland, 31-530
  • Pulawy, Poland, 24-100
  • Warsaw, Poland, 02-005
  • Wiecbork, Poland, 89-410
• Russian Federation
  • Moscow, Russian Federation, 125206
  • Moscow, Russian Federation, 111020
  • Moscow, Russian Federation, 111123
  • Moscow, Russian Federation, 119435
  • St. Petersburg, Russian Federation, 197089
  • St. Petersburg, Russian Federation, 198013
• Slovakia
  • Nitra, Slovakia, 949 01
  • Piestany, Slovakia, 921 01
  • Presov, Slovakia, 080 01
  • Skalica, Slovakia, 909 82
  • Trencin, Slovakia, 911 01
  • Zilina, Slovakia
• United Kingdom
  • Birmingham, United Kingdom, B15 2SQ
  • Bristol, United Kingdom, BS10 5NB
  • Bristol, United Kingdom, BS2 8HW
  • Cardiff, United Kingdom, CF14 5GJ
  • Chorley, United Kingdom, PR7 7NA
  • Glasgow, United Kingdom, G20 0XA
  • Glasgow, United Kingdom, G81 2DR
  • Liverpool, United Kingdom, L22 0LG
  • Manchester, United Kingdom, M15 6SX
  • Northwood, United Kingdom, HA6 2RN
  • Nottingham, United Kingdom, NG5 1PB
  • Plymouth, United Kingdom, PL6 8DH
  • Reading, United Kingdom, RG2 0TG
  • Reading, United Kingdom, RG1 5AN
  • Reading, United Kingdom, RG2 7AG
  • Sheffield, United Kingdom, S10 2JF
  • Taunton, United Kingdom, TA1 5DA
  • Torquay, United Kingdom, TQ2 7AA

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 45 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Voiding and storage symptoms diagnosed as LUTS associated with BPH for ≥ 3 months
• A total International Prostate Symptom Score (IPSS) of ≥13
• A maximum urinary flow rate of ≥4.0 mL/s and ≤12.0 mL/s, with voided volume of ≥120 mL during free flow
• A micturition frequency of ≥8 and at least 2 episodes of urgency with Patient Perception of the Intensity of Urgency Scale grade 3 or 4 per day on average on the 3 day micturition diary (at randomization)

Exclusion Criteria:

• Any significant Post Void Residual volume (>150 mL)
• A prostate with estimated weight ≥75 ml as assessed by transvesical or transrectal ultrasound
• Evidence of a symptomatic urinary tract infection

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo; Participants received 3 tablets once a day for 12 weeks. Placebo tamsulosin hydrochloride oral controlled absorption system (OCAS) 0.4 mg tablet; Placebo fixed dose combination (FDC) tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg tablet; Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg tablet	Drug: Placebo tamsulosin hydrochloride OCAS 0.4 mg; tablet; Drug: Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg; tablet; Drug: Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg; tablet
Active Comparator: TOCAS 0.4 mg; Participants received 3 tablets once a day for 12 weeks. Tamsulosin hydrochloride OCAS (TOCAS) 0.4 mg tablet; Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg tablet; Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg tablet	Drug: Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg; tablet; Drug: Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg; tablet; Drug: tamsulosin hydrochloride OCAS 0.4 mg; tablet; Other Names: Flomax®; Harnal ®; Omnic®; YM617
Experimental: FDC 0.4 mg/6 mg; Participants received 3 tablets once a day for 12 weeks. Placebo TOCAS 0.4 mg tablet; FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg tablet; Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg tablet	Drug: Placebo tamsulosin hydrochloride OCAS 0.4 mg; tablet; Drug: Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg; tablet; Drug: tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg); tablet; Other Names: Vesomni; EC905
Experimental: FDC 0.4 mg/9 mg; Participants received 3 tablets once a day for 12 weeks. Placebo TOCAS 0.4 mg tablet; Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg tablet; FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg tablet	Drug: Placebo tamsulosin hydrochloride OCAS 0.4 mg; tablet; Drug: Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg; tablet; Drug: tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg); tablet; Other Names: EC905

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline to End of Treatment in Total International Prostate Symptom Score	The International Prostate Symptom Score (IPSS) is a validated global questionnaire to assess the degree of urinary symptoms, based on answers to 7 questions concerning urinary symptoms: •Incomplete emptying of the bladder •Intermittency •Weak stream •Hesitancy •Frequency •Urgency •Nocturia Each question is assigned points from 0 to 5 indicating increasing severity of the symptom. Total score can range from 0 to 35 (mildly symptomatic to severely symptomatic).	Baseline and Week 12
Change From Baseline to End of Treatment in Total Urgency Frequency Score (TUFS, Previously Known as Total Urgency Score [TUS])	The Patient Perception of the Intensity of Urgency Scale (PPIUS) is a validated scale completed as part of the micturition diary. For each micturition and/or incontinence episode, the participant rated the degree of associated urgency according to the following 5-point categorical scale: - 0. No urgency; - 1. Mild urgency; - 2. Moderate urgency; - 3. Severe urgency; - 4. Urgency incontinence TUFS was calculated as the sum of the PPIUS gradings from the 3-day diary divided by the number of days on which urgency grading was recorded. Higher scores indicate more severe urgency.	Baseline and Week 12

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline to End of Treatment in Mean Number of Micturitions Per 24 Hours	A micturition is any voluntary urination, excluding episodes of incontinence only.The mean number of micturitions per 24 hours was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit.	Baseline and Week 12
Change From Baseline to End of Treatment in Mean Voided Volume Per Micturition	A micturition is any voluntary urination, excluding episodes of incontinence only. The mean volume voided per micturition was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit.	Baseline and Week 12
Change From Baseline to End of Treatment in Maximum Volume Voided Per Micturition	A micturition is any voluntary urination, excluding episodes of incontinence only. The maximum volume voided per micturition was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit.	Baseline and Week 12
Change From Baseline to End of Treatment in Mean Number of Urgency Episodes (PPIUS Grade 3 or 4) Per 24 Hours	An urgency episode is defined as an episode of strong desire to void accompanied by fear of leakage or pain. The mean number of urgency episodes with PPIUS grade 3 (Severe urgency) or 4 (Urgency incontinence) per 24 hours was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit.	Baseline and Week 12
Change From Baseline to End of Treatment in Mean Number of Urgency Incontinence Episodes Per 24 Hours	An urgency incontinence episode is defined as an episode with any involuntary leakage of urine accompanied by or immediately preceded by urgency. The mean number of urgency incontinence episodes with PPIUS grade 3 (Severe incontinence) or 4 (Urgency incontinence) per 24 hours was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit.	Baseline and Week 12
Change From Baseline to End of Treatment in Mean Number of Incontinence Episodes Per 24 Hours	An incontinence episode is defined as an episode with any involuntary loss of urine. The mean number of incontinence episodes per 24 hours was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit.	Baseline and Week 12
Change From Baseline to End of Treatment in Mean Number of Nocturia Episodes Per 24 Hours	A nocturia episode is defined as waking up at night to void (i.e., any voiding associated with sleep disturbance between the time the participant goes to bed with the intention to sleep until the time the patient gets up in the morning with the intention to stay awake). The mean number of nocturia episodes per 24 hours was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit.	Baseline and Week 12
Change From Baseline to End of Treatment in Mean Number of Pads Used Per 24 Hours	The mean number of pads per 24 hours was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit.	Baseline and Week 12
Change From Baseline to End of Treatment in IPSS Voiding Score	The IPSS is a validated global questionnaire to assess the degree of urinary symptoms based on answers to 7 questions. Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom. The voiding score is the sum of the responses to 4 voiding questions (incomplete emptying of the bladder, intermittency, weak stream, hesitancy) and ranges from 0 to 20 (mildly symptomatic to severely symptomatic).	Baseline and Week 12
Change From Baseline to End of Treatment in IPSS Storage Score	The IPSS is a validated global questionnaire to assess the degree of urinary symptoms based on answers to 7 questions concerning urinary symptoms. Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom. The storage symptom score is the sum of the responses to 3 storage questions (frequency, urgency and nocturia) and ranges from 0 to 15 (mildly symptomatic to severely symptomatic).	Baseline and Week 12
Change From Baseline to End of Treatment in IPSS QoL Score	The QoL assessment was a single question asking the participant how he would feel about tolerating his current level of symptoms for the rest of his life. The answers ranged from 0 to 6 (delighted to terrible).	Baseline and Week 12
Change From Baseline to End of Treatment in Symptom Bother Score	The Overactive Bladder Questionnaire (OAB-q) is a self-reported questionnaire with items relating to Symptom Bother and health-related quality of life (HRQoL). The Symptom Bother portion consists of an 8-item scale scored from 1 to 6. The total symptom bother score was calculated from the 8 answers and then transformed to range from 0 to 100, with 100 indicating worst severity. A negative change from baseline indicates an improvement.	Baseline and Week 12
Percentage of Participants Who Were OAB-q Responders at End of Treatment	A OAB-q responder was defined as a participant with an improvement from baseline in HRQoL subscale total score ≥ 10.	Week 12 (end of treatment)
Change From Baseline to End of Treatment in EQ-5D Visual Analogue Scale (VAS) Score	Visual Analogue Scale (VAS) is part of the EQ-5D questionnaire. The VAS is self-rated by the participant ranging from 0 to 100 (worst imaginable health state to best imaginable health state).	Baseline and Week 12
Patient Global Impression Scale at End of Treatment: Overall Bladder Symptoms	The Patient Global Impression (PGI) is a global questionnaire completed by the participant to assess both the change in the participants overall condition and the change in bladder symptoms since the start of the study. The questionnaire consists of 2 questions with 7 response levels ranging from 1 to 7 (very much improved to very much worse).	Baseline and Week 12
Patient Global Impression Scale at End of Treatment: General Health	The Patient Global Impression (PGI) is a global questionnaire completed by the participant to assess both the change in the participants overall condition and the change in bladder symptoms since the start of the study. The questionnaire consists of 2 questions with 7 response levels ranging from 1 to 7 (very much improved to very much worse).	Baseline and Week 12
Clinician Global Impression Scale at End of Treatment: Overall Bladder Symptoms	The Clinician Global Impression (CGI) is a questionnaire completed by the physician to assess change in the participants bladder symptoms since the start of the study. The questionnaire consists of 1 question with 7 response levels ranging from 1 to 7 (very much improved to very much worse).	Baseline and Week 12
Number of Participants With Adverse Events (AEs)	Safety is monitored by collecting AEs, which include abnormal laboratory parameters, vital signs or ECG data if the abnormality induced clinical signs or symptoms, needed active intervention, interruption or discontinuation of study medication or was clinically significant. A serious AE (SAE) was an event resulting in death, persistent or significant disability/incapacity or congenital anomaly or birth defect, was life-threatening, required or prolonged hospitalization or was considered medically important. AEs were assessed by the Investigator for intensity as mild (no disruption of normal daily activities), moderate (affected normal daily activities) or severe (inability to perform daily activities) and for causal relationship to study drug. A treatment-emergent adverse event (TEAE) was defined as an AE that occurred after administration of the first dose of double-blind study drug until 14 days after the last dose of double-blind study drug.	From first dose of double-blind study drug up to 14 days of last dose of double-blind study drug (up to 14 weeks)
Change From Baseline to End of Treatment in Post Void Residual (PVR) Volume	PVR volume is the volume of urine retained after voiding. PVR volume was assessed by ultrasonography or bladder scan.	Baseline and Week 12
Change From Baseline to End of Treatment in Maximum Flow Rate (Qmax)	Qmax during a micturition (urination) was recorded using uroflowmetry.	Baseline and Week 12
Change From Baseline to End of Treatment in Average Flow Rate (Qmean)	Qmean during a micturition (urination) was recorded using uroflowmetry.	Baseline and Week 12
Apparent Clearance (CL/F) of Tamsulosin		Week 4, Week 8 and Week 12
Maximum Concentration at Steady State (Cmaxss) of Tamsulosin		Week 4, Week 8 and Week 12
Minimum Concentration at Steady State (Cminss) of Tamsulosin		Week 4, Week 8 and Week 12
Time of Maximum Concentration at Steady State (Tmaxss) of Tamsulosin		Week 4, Week 8 and Week 12
Area Under the Curve at Steady State (AUCss) of Tamsulosin		Week 4, Week 8 and Week 12 (collection time points: trough, 1-3 hours post dose, 4-5 hours post-dose and 7-10 hours post-dose)
CL/F of Solifenacin		Week 4, Week 8 and Week 12
Cmaxss of Solifenacin		Week 4, Week 8 and Week 12
Cminss of Solifenacin		Week 4, Week 8 and Week 12
Tmaxss of Solifenacin		Week 4, Week 8 and Week 12
AUCss of Solifenacin		Week 4, Week 8 and Week 12 (collection time points: trough, 1-3 hours post dose, 4-5 hours post-dose and 7-10 hours post-dose)
Change From Baseline to End of Treatment in Individual IPSS Scores	The IPSS is a validated global questionnaire to assess the degree of urinary symptoms, based on answers to 7 questions concerning urinary symptoms: •Incomplete emptying of the bladder •Intermittency •Weak stream •Hesitancy •Frequency •Urgency •Nocturia Each question is assigned points from 0 to 5 indicating increasing severity of the symptom.	Baseline and Week 12
Change From Baseline to End of Treatment in Health Related QoL (HRQoL) Subscale: Coping Score	The Overactive Bladder Questionnaire (OAB-q) is a self-reported questionnaire with items relating to Symptom Bother and health-related quality of life (HRQoL). The HRQoL portion consists of an 25-item HRQoL subscale containing the following domains scored from 1 to 6: - coping - concern - sleep - social interaction Coping score can range from 8 to 48 (none of the time to all of the time) and transformed to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicates an improvement.	Baseline and Week 12
Change From Baseline to End of Treatment in HRQoL Subscale: Concern Score	The Overactive Bladder Questionnaire (OAB-q) is a self-reported questionnaire with items relating to Symptom Bother and health-related quality of life (HRQoL). The HRQoL portion consists of an 25-item HRQoL subscale containing the following domains scored from 1 to 6: •coping •concern •sleep •social interaction Concern score can range from 8 to 48 (none of the time to all of the time) and transformed to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicates an improvement.	Baseline and Week 12
Change From Baseline to End of Treatment in HRQoL Subscale: Sleep Score	The Overactive Bladder Questionnaire (OAB-q) is a self-reported questionnaire with items relating to Symptom Bother and health-related quality of life (HRQoL). The HRQoL portion consists of an 25-item HRQoL subscale containing the following domains scored from 1 to 6: •coping •concern •sleep •social interaction Sleep score can range from 8 to 48 (none of the time to all of the time) and transformed to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicates an improvement.	Baseline and Week 12
Change From Baseline to End of Treatment in HRQoL Subscale: Social Score	The Overactive Bladder Questionnaire (OAB-q) is a self-reported questionnaire with items relating to Symptom Bother and health-related quality of life (HRQoL). The HRQoL portion consists of an 25-item HRQoL subscale containing the following domains scored from 1 to 6: •coping •concern •sleep •social interaction Social score can range from 8 to 48 (none of the time to all of the time) and transformed to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicates an improvement.	Baseline and Week 12
Change From Baseline to End of Treatment in HRQoL Subscale: Total Score	The Overactive Bladder Questionnaire (OAB-q) is a self-reported questionnaire with items relating to Symptom Bother and health-related quality of life (HRQoL). The HRQoL portion consists of an 25-item HRQoL subscale containing the following domains scored from 1 to 6: •coping •concern •sleep •social interaction Total score is calculated by adding the 4 HRQoL subscale scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicates an improvement.	Baseline and Week 12
Change From Baseline to End of Treatment in EQ-5D Mobility Score	The European quality of life-5 dimensions (EQ-5D) is an international standardized non-disease specific instrument for describing and valuing health status. The EQ5D has 5 domains: - mobility - self-care - usual activity - pain/discomfort - anxiety/depression Each domain has 3 response levels (1= no problem, 2= some problems, 3 = confined to bed).	Baseline and Week 12
Change From Baseline to End of Treatment in EQ-5D Self-care Score	The European quality of life-5 dimensions (EQ-5D) is an international standardized non-disease specific instrument for describing and valuing health status. The EQ5D has 5 domains: - mobility - self-care - usual activity - pain/discomfort - anxiety/depression Each domain has 3 response levels (1= no problem, 2= some problems, 3 = unable to wash/dress).	Baseline and Week 12
Change From Baseline to End of Treatment in EQ-5D Usual Activities Score	The European quality of life-5 dimensions (EQ-5D) is an international standardized non-disease specific instrument for describing and valuing health status. The EQ5D has 5 domains: - mobility - self-care - usual activity - pain/discomfort - anxiety/depression Each domain has 3 response levels (1= no problem, 2= some problems, 3 = unable to perform usual activities).	Baseline and Week 12
Change From Baseline to End of Treatment in EQ-5D Pain/Discomfort Score	The European quality of life-5 dimensions (EQ-5D) is an international standardized non-disease specific instrument for describing and valuing health status. The EQ5D has 5 domains: - mobility - self-care - usual activity - pain/discomfort - anxiety/depression Each domain has 3 response levels (1= no pain, 2= moderate pain, 3 = extreme pain).	Baseline and Week 12
Change From Baseline to End of Treatment in EQ-5D Anxiety/Depression Score	The European quality of life-5 dimensions (EQ-5D) is an international standardized non-disease specific instrument for describing and valuing health status. The EQ5D has 5 domains: - mobility - self-care - usual activity - pain/discomfort - anxiety/depression Each domain has 3 response levels (1= not anxious, 2= moderately anxious, 3 = extremely anxious).	Baseline and Week 12

Collaborators and Investigators

• Sponsor: Astellas Pharma Europe B.V.
• Investigators: Study Chair: Use Central Contact, Astellas Pharma Global Development

Publications and helpful links

General Publications

• van Kerrebroeck P, Chapple C, Drogendijk T, Klaver M, Sokol R, Speakman M, Traudtner K, Drake MJ; NEPTUNE Study Group. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol. 2013 Dec;64(6):1003-12. doi: 10.1016/j.eururo.2013.07.034. Epub 2013 Aug 3.

Helpful Links

• Link to results on Astellas Clinical Study Results website

Study record dates

Study Major Dates

• Study Start (Actual): January 11, 2010
• Primary Completion (Actual): March 1, 2011
• Study Completion (Actual): March 1, 2011

Study Registration Dates

• First Submitted: November 19, 2009
• First Submitted That Met QC Criteria: November 19, 2009
• First Posted (Estimated): November 23, 2009

Study Record Updates

• Last Update Posted (Actual): December 3, 2024
• Last Update Submitted That Met QC Criteria: November 12, 2024
• Last Verified: November 1, 2024

More Information

Terms related to this study

• Keywords: Treatment; Benign Prostatic Hyperplasia; Lower Urinary Tract Symptoms; Solifenacin succinate; EC905; Vesomni; Tamsulosin hydrochloride OCAS
• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Pathologic Processes; Genital Diseases, Male; Prostatic Diseases; Male Urogenital Diseases; Urological Manifestations; Prostatic Hyperplasia; Hyperplasia; Lower Urinary Tract Symptoms; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Neurotransmitter Agents; Adrenergic Agents; Urological Agents; Adrenergic Antagonists; Muscarinic Antagonists; Cholinergic Antagonists; Cholinergic Agents; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Tamsulosin; Solifenacin Succinate
• Other Study ID Numbers: 905-CL-055; 2008-001211-37 (Other Identifier: EudraCT)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
• IPD Sharing Time Frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
• IPD Sharing Access Criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; CSR